Akebia Therapeutics, Inc. (Nasdaq: AKBA) has initiated a Phase 2 basket trial to evaluate ebribafusp, an investigational complement inhibitor, in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE